Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigator want to demonstrate that this is an useful and efficient method.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Routine Fetal RhD Genotyping for RhD- Pregnant Women
NCT00832962
Prospective Collection of Whole Blood Specimens From RhD Negative Pregnant Women
NCT06690099
Evaluation of a Noninvasive Fetal RHD Genotyping Test
NCT01054716
Non Invasive Prenatal Test of Rare Genetic Diseases: Application to Rare Intellectual Disabilities
NCT03688594
Development of New Prenatal Diagnostic Tests From Maternal Blood
NCT00314691
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I'm going to check the clinical history of all negative RhD pregnant women since January 2013 until December 2015.
I'll check if prenatal determination matches with postnatal RhD determination of newborn.
Usually, when a RhD negative woman is pregnant we administrate gammaglobulin in 28 gestation weeks, after invasive procedures and after delivery if the baby is positive RhD.
Althought, the investigators know that the 40 percent of RhD negative pregnant have a negative RhD baby.
This study will do posible to know how many gammaglobulins hasn't been necessary thanks to prenatal determination.
This is an important thing because gammaglobulin is an humanoid product ( it isn't without heatlth risks,...) and because is expensive.
For this reason, if the investigators do universal determination of RhD fetal genotype the investigators can avoid the administration of humanoid product in pregnant women.
I want to demonstrate that this practice is very useful and efficient in our population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIBSP-RHD-2016-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.